Previous 10 | Next 10 |
WALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced that on December 6, 2023, it entered into privately negotiated exchange and/or subscription agreements with certain holders of its outstanding 0.375% Convertible Senior Notes due 2024 (the ȁ...
WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2022 Sustainability Report and related reporting index disclosures. Themed “ Making...
WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2022 Sustainability Report and related reporting index disclosures. Themed “ Making...
WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of TangenX® SC, the industry’s first holder-free, self-contained Tangential Flow Filtrati...
2023-11-02 04:19:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Discovery Fund was down 5.4% during Q3, which was 2.0% better than the Benchmark...
2023-10-31 13:16:08 ET Repligen Corporation (RGEN) Q3 2023 Earnings Conference Call October 31, 2023 8:30 AM ET Company Participants Sondra Newman – Head of Investor Relations Tony Hunt – Chief Executive Officer Jason Garland – Chief Financia...
Repligen Corporation (NASDAQ: RGEN) is one of today's top gainers. The company's shares are currently up -4.79% on the day to $113.85. Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Euro...
2023-10-31 07:32:39 ET More on Repligen Repligen: Current Market Values Well Supported, Valuations Are Not, Reiterate Hold Repligen Corporation (RGEN) Q2 2023 Earnings Call Transcript Repligen Q3 2023 Earnings Preview Repligen beats bottom line, but misses to...
Reports total third quarter revenues of $141.2 million, with base business revenues of $140.1 million Orders strengthened with total book-to-bill ratio of 1.07 Narrows full year revenue guidance to range of $635-$645 million WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE)...
Tennant Company (TNC) is expected to report for Q3 2023 Stellantis N.V. (STLA) is expected to report for Q3 2023 Marathon Petroleum Corporation (MPC) is expected to report $7.79 for Q3 2023 Easterly Government Properties Inc. (DEA) is expected to report $0.29 for Q3 2023 Allegion ...
News, Short Squeeze, Breakout and More Instantly...
WALTHAM, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2024 financial results on Tuesday, July 30, 2024. The Company will issue a press release before the market opens and will host a conference call at ...
2024-07-04 04:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-21 14:00:08 ET Daniel Arias from Stifel Nicolaus issued a price target of $207.00 for RGEN on 2024-06-21 12:12:00. The adjusted price target was set to $207.00. At the time of the announcement, RGEN was trading at $123.16. The overall price target consensus is at...